{"id":"lidocaine-hydrochloride-preservative-free","_fda":{"id":"10e6f471-d23a-2a9a-e063-6394a90acd55","set_id":"0050d05a-b8e9-c544-e063-6294a90a0243","openfda":{"upc":["0368071344905"],"unii":["V13007Z41A"],"route":["ORAL","TOPICAL"],"rxcui":["1010739"],"spl_id":["10e6f471-d23a-2a9a-e063-6394a90acd55"],"brand_name":["Lidocaine Hydrochloride"],"spl_set_id":["0050d05a-b8e9-c544-e063-6294a90a0243"],"package_ndc":["68071-3449-2"],"product_ndc":["68071-3449"],"generic_name":["LIDOCAINE HYDROCHLORIDE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["LIDOCAINE HYDROCHLORIDE"],"manufacturer_name":["NuCare Pharmaceuticals,Inc."],"application_number":["ANDA088802"],"original_packager_product_ndc":["0054-3500"]},"version":"2","warnings":["WARNINGS EXCESSIVE DOSAGE, OR SHORT INTERVALS BETWEEN DOSES, CAN RESULT IN HIGH PLASMA LEVELS AND SERIOUS ADVERSE EFFECTS. PATIENTS SHOULD BE INSTRUCTED TO STRICTLY ADHERE TO THE RECOMMENDED DOSAGE AND ADMINISTRATION GUIDELINES AS SET FORTH IN THIS PACKAGE INSERT. THE MANAGEMENT OF SERIOUS ADVERSE REACTIONS MAY REQUIRE THE USE OF RESUSCITATIVE EQUIPMENT, OXYGEN, AND OTHER RESUSCITATIVE DRUGS. Lidocaine should be used with extreme caution if the mucosa in the area of application has been traumatized, since under such conditions there is the potential for rapid systemic absorption. Life-threatening and fatal events in infants and young children Postmarketing cases of seizures, cardiopulmonary arrest, and death in patients under the age of 3 years have been reported with use of Lidocaine Viscous 2% when it was not administered in strict adherence to the dosing and administration recommendations. In the setting of teething pain, Lidocaine Viscous 2% should generally not be used. For other conditions, the use of the product in patients less than 3 years of age should be limited to those situations where safer alternatives are not available or have been tried but failed. Methemoglobinemia Cases of methemoglobinemia have been reported in association with local anesthetic use. Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months of age, and concurrent exposure to oxidizing agents or their metabolites are more susceptible to developing clinical manifestations of the condition. If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended. Signs of methemoglobinemia may occur immediately or may be delayed some hours after exposure, and are characterized by a cyanotic skin discoloration and/or abnormal coloration of the blood. Methemoglobin levels may continue to rise; therefore, immediate treatment is required to avert more serious central nervous system and cardiovascular adverse effects, including seizures, coma, arrhythmias, and death. Discontinue Lidocaine Viscous 2% and any other oxidizing agents. Depending on the severity of the signs and symptoms, patients may respond to supportive care, i.e., oxygen therapy, hydration. A more severe clinical presentation may require treatment with methylene blue, exchange transfusion, or hyperbaric oxygen."],"pregnancy":["Pregnancy Teratogenic Effects Pregnancy Category B: Reproduction studies have been performed in rats at doses up to 6.6 times the human dose and have revealed no evidence of harm to the fetus caused by lidocaine. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used in pregnancy only if clearly needed."],"overdosage":["OVERDOSAGE Acute emergencies from local anesthetics are generally related to high plasma levels encountered during therapeutic use of local anesthetics. (See ADVERSE REACTIONS , WARNINGS , and PRECAUTIONS ) Management of Local Anesthetic Emergencies The first consideration is prevention, best accomplished by careful and constant monitoring of cardiovascular and respiratory vital signs and the patient’s state of consciousness after each local anesthetic administration. The first step in the management of convulsions consist of immediate attention to the maintenance of a patent airway and assisted or controlled ventilation with oxygen. In situations where trained personnel are readily available, ventilation should be maintained and oxygen should be delivered by a delivery system capable of permitting immediate positive airway pressure by mask. Immediately after the institution of these ventilatory measures, the adequacy of the circulation should be evaluated, keeping in mind that drugs used to treat convulsions sometimes depress the circulation when administered intravenously. Should convulsions persist despite adequate respiratory support, and if the status of the circulation permits, small increments of an ultra-short acting barbiturate (such as thiopental or thiamylal) or a benzodiazepine (such as diazepam) may be administered intravenously. The clinician should be familiar, prior to use of local anesthetics, with these anticonvulsant drugs. Supportive treatment of circulatory depression may require administration of intravenous fluids and, when appropriate, a vasopressor as indicated by the clinical situation (e.g., ephedrine). If not treated immediately, both convulsions and cardiovascular depression can result in hypoxia, acidosis, bradycardia, arrhythmias and cardiac arrest. If cardiac arrest should occur, standard cardiopulmonary resuscitative measures should be instituted. Dialysis is of negligible value in the treatment of acute overdosage with lidocaine. The oral LD 50 of lidocaine in non-fasted female rats is 459 (346 to 773) mg/kg (as the salt) and 214 (159 to 324) mg/kg (as the salt) in fasted female rats."],"description":["DESCRIPTION Lidocaine Viscous 2% (Lidocaine Hydrochloride Oral Topical Solution USP) contains a local anesthetic agent and is administered topically. Lidocaine Viscous 2% (Lidocaine Hydrochloride Oral Topical Solution USP) contains lidocaine hydrochloride, which is chemically designated as acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)-,monohydrochloride, and has the following structural formula: The molecular formula of lidocaine is C 14 H 22 N 2 O. The molecular weight is 234.34. Composition of Solution : Each mL contains 20 mg (2%) of lidocaine hydrochloride USP and the following inactive ingredients: carboxymethylcellulose sodium, flavoring, methylparaben, propylparaben, purified water and saccharin sodium. chem-structure.jpg"],"precautions":["PRECAUTIONS Information for Patients Parents and caregivers should be cautioned about the following: For patients under 3 years of age, special care must be given to accurately measuring the prescribed dose and not administering the product more often than prescribed. To ensure accuracy, we recommend you use a measuring device to carefully measure the correct volume. The product should only be used for the prescribed indication. To reduce the risk of accidental ingestion, the product container should be tightly closed and the product should be stored well out of reach of all children immediately after each use. If the patient shows signs of systemic toxicity (e.g., lethargy, shallow breathing, seizure activity) emergency medical attention should besought immediately and no additional product should be administered. Unused product should be discarded in a manner that prevents possible exposure to children and pets. All patients should be aware that when topical anesthetics are used in the mouth or throat, the production of topical anesthesia may impair swallowing and thus enhance the danger of aspiration. For this reason, food should not be ingested for 60 minutes following use of local anesthetic preparations in the mouth or throat area. This is particularly important in children because of their frequency of eating. Numbness of the tongue or buccal mucosa may increase the danger of biting trauma. For this reason food and/or chewing gum should not be used while the mouth or throat area is anesthetized. Inform patients that use of local anesthetics may cause methemoglobinemia, a serious condition that must be treated promptly. Advise patients or caregivers to seek immediate medical attention if they or someone in their care experience the following signs or symptoms: pale, gray, or blue colored skin (cyanosis); headache; rapid heart rate; shortness of breath; lightheadedness; or fatigue. General The safety and effectiveness of lidocaine depend on proper dosage, correct technique, adequate precautions, and readiness for emergencies (see WARNINGS and ADVERSE REACTIONS ). The lowest dosage that results in effective anesthesia should be used to avoid high plasma levels and serious adverse effects. Repeated doses of lidocaine may cause significant increases in blood levels with each repeated dose because of slow accumulation of the drug and/or its metabolites. Tolerance varies with the status of the patient. Debilitated, elderly patients, acutely ill patients, and children should be given reduced doses commensurate with their age, weight and physical condition. Lidocaine should also be used with caution in patients with severe shock or heart block. Lidocaine should be used with caution in persons with known drug sensitivities. Patients allergic to paraaminobenzoic acid derivatives (procaine, tetracaine, benzocaine, etc.) have not shown cross sensitivity to lidocaine. Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia: Class Examples Nitrates/Nitrites nitroglycerin, nitroprusside, nitric oxide, nitrous oxide Local anesthetics benzocaine, lidocaine, bupivacaine, mepivacaine, tetracaine, prilocaine, procaine, articaine, ropivacaine Antineoplastic agents cyclophosphamide, flutamide, rasburicase, ifosfamide, hydroxyurea Antibiotics dapsone, sulfonamides, nitrofurantoin, para-aminosalicylic acid Antimalarials chloroquine, primaquine Anticonvulsants phenytoin, sodium valproate, phenobarbital Other drugs acetaminophen, metoclopramide, sulfasalazine, quinine Carcinogenesis, Mutagenesis, Impairment of Fertility Studies of lidocaine in animals to evaluate the carcinogenic and mutagenic potential or the effect on fertility have not been conducted. Pregnancy Teratogenic Effects Pregnancy Category B: Reproduction studies have been performed in rats at doses up to 6.6 times the human dose and have revealed no evidence of harm to the fetus caused by lidocaine. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used in pregnancy only if clearly needed. Nursing Mothers It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when lidocaine is administered to nursing women. Pediatric Use Dosage in children should be reduced, commensurate with age, body weight and physical conditions. See DOSAGE AND ADMINISTRATION ."],"how_supplied":["HOW SUPPLIED Lidocaine Viscous 2% (Lidocaine Hydrochloride Oral Topical Solution USP) The 2% oral topical solution is supplied as a clear, colorless, viscous solution . NDC 68071-3449-0: Squeeze Bottle of 100 mL Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Dispense in a child-resistant container as defined in the USP/NF. SHAKE WELL BEFORE USE. Distr. by: West-Ward Pharmaceuticals Corp. Eatontown, NJ 07724 4055408//11 Revised October 2018"],"boxed_warning":["WARNING: Life-threatening and fatal events in infants and young children Postmarketing cases of seizures, cardiopulmonary arrest, and death in patients under the age of 3 years have been reported with use of Lidocaine Viscous 2% when it was not administered in strict adherence to the dosing and administration recommendations. In the setting of teething pain, Lidocaine Viscous 2% should generally not be used. For other conditions, the use of the product in patients less than 3 years of age should be limited to those situations where safer alternatives are not available or have been tried but failed. To decrease the risk of serious adverse events with use of Lidocaine Viscous 2%, instruct caregivers to strictly adhere to the prescribed dose and frequency of administration and store the prescription bottle safely out of reach of children."],"pediatric_use":["Pediatric Use Dosage in children should be reduced, commensurate with age, body weight and physical conditions. See DOSAGE AND ADMINISTRATION ."],"effective_time":"20240208","nursing_mothers":["Nursing Mothers It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when lidocaine is administered to nursing women."],"adverse_reactions":["ADVERSE REACTIONS Adverse experiences following the administration of lidocaine are similar in nature to those observed with other amide local anesthetic agents. These adverse experiences are, in general, dose-related and may result from high plasma levels caused by excessive dosage or rapid absorption, or may result from a hypersensitivity, idiosyncrasy or diminished tolerance on the part of the patient. Serious adverse experiences are generally systemic in nature. The following types are those most commonly reported: Central Nervous System CNS manifestations are excitatory and/or depressant and may be characterized by lightheadedness, nervousness, apprehension, euphoria, confusion, dizziness, drowsiness, tinnitus, blurred or double vision, vomiting, sensations of heat, cold or numbness, twitching, tremors, convulsions, unconsciousness, respiratory depression and arrest. The excitatory manifestations may be very brief or may not occur at all, in which case the first manifestation of toxicity may be drowsiness merging into unconsciousness and respiratory arrest. Drowsiness following the administration of lidocaine is usually an early sign of a high blood level of the drug and may occur as a consequence of rapid absorption. Cardiovascular System Cardiovascular manifestations are usually depressant and are characterized by bradycardia, hypotension, and cardiovascular collapse, which may lead to cardiac arrest. Allergic Allergic reactions are characterized by cutaneous lesions, urticaria, edema or anaphylactoid reactions. Allergic reactions may occur as a result of sensitivity either to the local anesthetic agent or to the methylparaben and/or propylparaben used in this formulation. Allergic reactions as a result of sensitivity to lidocaine are extremely rare and, if they occur, should be managed by conventional means. The detection of sensitivity by skin testing is of doubtful value."],"contraindications":["CONTRAINDICATIONS Lidocaine is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type, or to other components of the solution."],"drug_interactions":["Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia: Class Examples Nitrates/Nitrites nitroglycerin, nitroprusside, nitric oxide, nitrous oxide Local anesthetics benzocaine, lidocaine, bupivacaine, mepivacaine, tetracaine, prilocaine, procaine, articaine, ropivacaine Antineoplastic agents cyclophosphamide, flutamide, rasburicase, ifosfamide, hydroxyurea Antibiotics dapsone, sulfonamides, nitrofurantoin, para-aminosalicylic acid Antimalarials chloroquine, primaquine Anticonvulsants phenytoin, sodium valproate, phenobarbital Other drugs acetaminophen, metoclopramide, sulfasalazine, quinine"],"precautions_table":["
ClassExamples
Nitrates/Nitritesnitroglycerin, nitroprusside, nitric oxide, nitrous oxide
Local anestheticsbenzocaine, lidocaine, bupivacaine, mepivacaine, tetracaine, prilocaine, procaine, articaine, ropivacaine
Antineoplastic agentscyclophosphamide, flutamide, rasburicase, ifosfamide, hydroxyurea
Antibioticsdapsone, sulfonamides, nitrofurantoin, para-aminosalicylic acid
Antimalarialschloroquine, primaquine
Anticonvulsants phenytoin, sodium valproate, phenobarbital
Other drugsacetaminophen, metoclopramide, sulfasalazine, quinine
"],"general_precautions":["General The safety and effectiveness of lidocaine depend on proper dosage, correct technique, adequate precautions, and readiness for emergencies (see WARNINGS and ADVERSE REACTIONS ). The lowest dosage that results in effective anesthesia should be used to avoid high plasma levels and serious adverse effects. Repeated doses of lidocaine may cause significant increases in blood levels with each repeated dose because of slow accumulation of the drug and/or its metabolites. Tolerance varies with the status of the patient. Debilitated, elderly patients, acutely ill patients, and children should be given reduced doses commensurate with their age, weight and physical condition. Lidocaine should also be used with caution in patients with severe shock or heart block. Lidocaine should be used with caution in persons with known drug sensitivities. Patients allergic to paraaminobenzoic acid derivatives (procaine, tetracaine, benzocaine, etc.) have not shown cross sensitivity to lidocaine."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY Mechanism of Action Lidocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action. Hemodynamics Excessive blood levels may cause changes in cardiac output, total peripheral resistance, and mean arterial pressure. These changes may be attributable to a direct depressant effect of the local anesthetic agent on various components of the cardiovascular system. The net effect is normally a modest hypotension when the recommended dosages are not exceeded. Pharmacokinetics and Metabolism Lidocaine is absorbed following topical administration to mucous membranes, its rate and extent of absorption being dependent upon concentration and total dose administered, the specific site of application, and duration of exposure. In general, the rate of absorption of local anesthetic agents following topical application occurs most rapidly after intratracheal administration. Lidocaine is also well-absorbed from the gastrointestinal tract, but little intact drug appears in the circulation because of biotransformation in the liver. The plasma binding of lidocaine is dependent on drug concentration, and the fraction bound decreases with increasing concentration. At concentrations of 1 to 4 mcg of free base per mL, 60 to 80 percent of lidocaine is protein bound. Binding is also dependent on the plasma concentration of the alpha-1-acid glycoprotein. Lidocaine crosses the blood-brain and placental barriers, presumably by passive diffusion. Lidocaine is metabolized rapidly by the liver, and metabolites and unchanged drug are excreted by the kidneys. Biotransformation includes oxidative N-dealkylation, ring hydroxylation, cleavage of the amide linkage, and conjugation. N-dealkylation, a major pathway of biotransformation, yields the metabolites monoethylglycinexylidide and glycinexylidide. The pharmacological/toxicological actions of these metabolites are similar to, but less potent than, those of lidocaine. Approximately 90% of lidocaine administered is excreted in the form of various metabolites, and less than 10% is excreted unchanged. The primary metabolite in urine is a conjugate of 4-hydroxy-2, 6-dimethylaniline. The elimination half-life of lidocaine following an intravenous bolus injection is typically 1.5 to 2 hours. Because of the rapid rate at which lidocaine is metabolized, any condition that affects liver function may alter lidocaine kinetics. The half-life may be prolonged two-fold or more in patients with liver dysfunction. Renal dysfunction does not affect lidocaine kinetics but may increase the accumulation of metabolites. Factors such as acidosis and the use of CNS stimulants and depressants affect the CNS levels of lidocaine required to produce overt systemic effects. Objective adverse manifestations become increasingly apparent with increasing venous plasma levels above 6 mcg free base per mL. In the rhesus monkey arterial blood levels of 18 to 21 mcg/mL have been shown to be threshold for convulsive activity."],"indications_and_usage":["INDICATIONS AND USAGE Lidocaine is indicated for the production of topical anesthesia of irritated or inflamed mucous membranes of the mouth and pharynx. It is also useful for reducing gagging during the taking of X-ray pictures and dental impressions."],"drug_interactions_table":["
ClassExamples
Nitrates/Nitritesnitroglycerin, nitroprusside, nitric oxide, nitrous oxide
Local anestheticsbenzocaine, lidocaine, bupivacaine, mepivacaine, tetracaine, prilocaine, procaine, articaine, ropivacaine
Antineoplastic agentscyclophosphamide, flutamide, rasburicase, ifosfamide, hydroxyurea
Antibioticsdapsone, sulfonamides, nitrofurantoin, para-aminosalicylic acid
Antimalarialschloroquine, primaquine
Anticonvulsants phenytoin, sodium valproate, phenobarbital
Other drugsacetaminophen, metoclopramide, sulfasalazine, quinine
"],"information_for_patients":["Information for Patients Parents and caregivers should be cautioned about the following: For patients under 3 years of age, special care must be given to accurately measuring the prescribed dose and not administering the product more often than prescribed. To ensure accuracy, we recommend you use a measuring device to carefully measure the correct volume. The product should only be used for the prescribed indication. To reduce the risk of accidental ingestion, the product container should be tightly closed and the product should be stored well out of reach of all children immediately after each use. If the patient shows signs of systemic toxicity (e.g., lethargy, shallow breathing, seizure activity) emergency medical attention should besought immediately and no additional product should be administered. Unused product should be discarded in a manner that prevents possible exposure to children and pets. All patients should be aware that when topical anesthetics are used in the mouth or throat, the production of topical anesthesia may impair swallowing and thus enhance the danger of aspiration. For this reason, food should not be ingested for 60 minutes following use of local anesthetic preparations in the mouth or throat area. This is particularly important in children because of their frequency of eating. Numbness of the tongue or buccal mucosa may increase the danger of biting trauma. For this reason food and/or chewing gum should not be used while the mouth or throat area is anesthetized. Inform patients that use of local anesthetics may cause methemoglobinemia, a serious condition that must be treated promptly. Advise patients or caregivers to seek immediate medical attention if they or someone in their care experience the following signs or symptoms: pale, gray, or blue colored skin (cyanosis); headache; rapid heart rate; shortness of breath; lightheadedness; or fatigue."],"spl_unclassified_section":["Rx only A topical anesthetic for the mucous membranes of the mouth and pharynx."],"dosage_and_administration":["DOSAGE AND ADMINISTRATION Adult The maximum recommended single dose of lidocaine for healthy adults should be such that the dose of lidocaine does not exceed 4.5 mg/kg or 2 mg/lb body weight and does not in any case exceed a total of 300 mg. For symptomatic treatment of irritated or inflamed mucous membranes of the mouth and pharynx, the usual adult dose is 15 mL undiluted. For use in the mouth, the solution should be swished around in the mouth and spit out. For use in the pharynx, the undiluted solution should be gargled and may be swallowed. This dose should not be administered at intervals of less than three hours, and not more than eight doses should be given in a 24-hour period. The dosage should be adjusted commensurate with the patient’s age, weight and physical condition (see PRECAUTIONS ). Pediatric Care must be taken to ensure correct dosage in all pediatric patients as there have been cases of overdose due to inappropriate dosing. It is difficult to recommend a maximum dose of any drug for children since this varies as a function of age and weight. For children over 3 years of age who have a normal lean body mass and normal body development, the maximum dose is determined by the child’s weight or age. For example: in a child of 5 years weighing 50 lbs., the dose of lidocaine should not exceed 75 to 100 mg (3.7 to 5 mL of lidocaine). For infants and in children under 3 years of age, the solution should be accurately measured and no more than 1.2 mL be applied to the immediate area with a cotton-tipped applicator. Wait at least 3 hours before giving the next dose; a maximum of four doses may be given in a 12-hour period. Lidocaine should only be used if the underlying condition requires treatment with a volume of product that is less than or equal to 1.2 mL."],"spl_product_data_elements":["Lidocaine Hydrochloride Lidocaine Hydrochloride METHYLPARABEN PROPYLPARABEN SACCHARIN SODIUM CARBOXYMETHYLCELLULOSE SODIUM, UNSPECIFIED FORM WATER LIDOCAINE HYDROCHLORIDE LIDOCAINE LIDOCAINE HYDROCHLORIDE ANHYDROUS"],"package_label_principal_display_panel":["Package/Label Display Panel pdp"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["Carcinogenesis, Mutagenesis, Impairment of Fertility Studies of lidocaine in animals to evaluate the carcinogenic and mutagenic potential or the effect on fertility have not been conducted."]},"safety":{"boxedWarnings":["WARNING: Life-threatening and fatal events in infants and young children Postmarketing cases of seizures, cardiopulmonary arrest, and death in patients under the age of 3 years have been reported with use of Lidocaine Viscous 2% when it was not administered in strict adherence to the dosing and administration recommendations. In the setting of teething pain, Lidocaine Viscous 2% should generally not be used. For other conditions, the use of the product in patients less than 3 years of age should be limited to those situations where safer alternatives are not available or have been tried but failed. To decrease the risk of serious adverse events with use of Lidocaine Viscous 2%, instruct caregivers to strictly adhere to the prescribed dose and frequency of administration and store the prescription bottle safely out of reach of children."],"safetySignals":[{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"4307 reports"},{"date":"","signal":"PAIN","source":"FDA FAERS","actionTaken":"3554 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"3527 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"3356 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"3158 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"3012 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"2630 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"2351 reports"},{"date":"","signal":"PNEUMONIA","source":"FDA FAERS","actionTaken":"2170 reports"},{"date":"","signal":"VOMITING","source":"FDA FAERS","actionTaken":"2121 reports"}],"drugInteractions":[{"drug":"nitroglycerin","action":"Monitor","effect":"Increased risk of methemoglobinemia"},{"drug":"nitroprusside","action":"Monitor","effect":"Increased risk of methemoglobinemia"},{"drug":"nitric oxide","action":"Monitor","effect":"Increased risk of methemoglobinemia"},{"drug":"nitrous oxide","action":"Monitor","effect":"Increased risk of methemoglobinemia"},{"drug":"benzocaine","action":"Avoid","effect":"Increased risk of methemoglobinemia"},{"drug":"lidocaine","action":"Avoid","effect":"Increased risk of methemoglobinemia"},{"drug":"bupivacaine","action":"Avoid","effect":"Increased risk of methemoglobinemia"},{"drug":"mepivacaine","action":"Avoid","effect":"Increased risk of methemoglobinemia"},{"drug":"tetracaine","action":"Avoid","effect":"Increased risk of methemoglobinemia"},{"drug":"prilocaine","action":"Avoid","effect":"Increased risk of methemoglobinemia"},{"drug":"procaine","action":"Avoid","effect":"Increased risk of methemoglobinemia"},{"drug":"articaine","action":"Avoid","effect":"Increased risk of methemoglobinemia"},{"drug":"ropivacaine","action":"Avoid","effect":"Increased risk of methemoglobinemia"},{"drug":"cyclophosphamide","action":"Monitor","effect":"Increased risk of methemoglobinemia"},{"drug":"flutamide","action":"Monitor","effect":"Increased risk of methemoglobinemia"},{"drug":"rasburicase","action":"Monitor","effect":"Increased risk of methemoglobinemia"},{"drug":"ifosfamide","action":"Monitor","effect":"Increased risk of methemoglobinemia"},{"drug":"hydroxyurea","action":"Monitor","effect":"Increased risk of methemoglobinemia"},{"drug":"dapsone","action":"Monitor","effect":"Increased risk of methemoglobinemia"},{"drug":"sulfonamides","action":"Monitor","effect":"Increased risk of methemoglobinemia"},{"drug":"nitrofurantoin","action":"Monitor","effect":"Increased risk of methemoglobinemia"},{"drug":"para-aminosalicylic acid","action":"Monitor","effect":"Increased risk of methemoglobinemia"},{"drug":"chloroquine","action":"Monitor","effect":"Increased risk of methemoglobinemia"},{"drug":"primaquine","action":"Monitor","effect":"Increased risk of methemoglobinemia"},{"drug":"phenytoin","action":"Monitor","effect":"Increased risk of methemoglobinemia"},{"drug":"sodium valproate","action":"Monitor","effect":"Increased risk of methemoglobinemia"},{"drug":"phenobarbital","action":"Monitor","effect":"Increased risk of methemoglobinemia"},{"drug":"acetaminophen","action":"Monitor","effect":"Increased risk of methemoglobinemia"},{"drug":"metoclopramide","action":"Monitor","effect":"Increased risk of methemoglobinemia"},{"drug":"sulfasalazine","action":"Monitor","effect":"Increased risk of methemoglobinemia"},{"drug":"quinine","action":"Monitor","effect":"Increased risk of methemoglobinemia"}],"commonSideEffects":[{"effect":"Lightheadedness","drugRate":"Not specified","severity":"mild"},{"effect":"Nervousness","drugRate":"Not specified","severity":"mild"},{"effect":"Apprehension","drugRate":"Not specified","severity":"mild"},{"effect":"Euphoria","drugRate":"Not specified","severity":"mild"},{"effect":"Confusion","drugRate":"Not specified","severity":"moderate"},{"effect":"Dizziness","drugRate":"Not specified","severity":"mild"},{"effect":"Drowsiness","drugRate":"Not specified","severity":"mild"},{"effect":"Tinnitus","drugRate":"Not specified","severity":"mild"},{"effect":"Blurred or double vision","drugRate":"Not specified","severity":"moderate"},{"effect":"Vomiting","drugRate":"Not specified","severity":"moderate"},{"effect":"Twitching","drugRate":"Not specified","severity":"moderate"},{"effect":"Tremors","drugRate":"Not specified","severity":"moderate"},{"effect":"Convulsions","drugRate":"Not specified","severity":"serious"},{"effect":"Respiratory depression and arrest","drugRate":"Not specified","severity":"serious"},{"effect":"Bradycardia","drugRate":"Not specified","severity":"serious"},{"effect":"Hypotension","drugRate":"Not specified","severity":"serious"},{"effect":"Cardiovascular collapse","drugRate":"Not specified","severity":"serious"},{"effect":"Cardiac arrest","drugRate":"Not specified","severity":"serious"},{"effect":"Urticaria","drugRate":"Not specified","severity":"mild"},{"effect":"Anaphylactoid reactions","drugRate":"Extremely rare","severity":"serious"}],"contraindications":["Known history of hypersensitivity to local anesthetics of the amide type","Hypersensitivity to other components of the solution"],"specialPopulations":{"Pregnancy":"Pregnancy Category B: Reproduction studies have been performed in rats at doses up to 6.6 times the human dose and have revealed no evidence of harm to the fetus caused by lidocaine. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used in pregnancy only if clearly needed.","Geriatric use":"Not provided in FDA text","Paediatric use":"Dosage in children should be reduced, commensurate with age, body weight and physical conditions.","Nursing mothers":"It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when lidocaine is administered to nursing women.","Renal impairment":"Not provided in FDA text","Hepatic impairment":"Not provided in FDA text"}},"_chembl":null,"patents":[],"_fixedAt":"2026-03-30T11:27:41.108228","_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Lidocaine Hydrochloride","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:48:59.443734+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:49:05.711938+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-19T23:48:58.566191+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lidocaine Hydrochloride","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:49:06.015613+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:48:56.180264+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (boxed_warning)","rawText":"WARNING: Life-threatening and fatal events in infants and young children Postmarketing cases of seizures, cardiopulmonary arrest, and death in patients under the age of 3 years have been reported with use of Lidocaine Viscous 2% when it was not administered in strict adherence to the dosing and administration recommendations. In the setting of teething pain, Lidocaine Viscous 2% should generally not be used. For other conditions, the use of the product in patients less than 3 years of age should","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:48:56.180295+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-19T23:49:08.638761+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Sodium channel alpha subunit blocker","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:49:08.039372+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1200409/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:49:07.549732+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA088802","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:48:56.180300+00:00"}},"allNames":"lidocaine hydrochloride preservative free","timeline":[{"date":"20130314","type":"positive","milestone":"FDA approval — EUGIA PHARMA","regulator":"FDA","description":""},{"date":"20250729","type":"positive","milestone":"FDA approval — AUROBINDO PHARMA LTD","regulator":"FDA","description":""},{"date":"19920408","type":"positive","milestone":"FDA approval — B BRAUN","regulator":"FDA","description":""},{"date":"20180803","type":"positive","milestone":"FDA approval — B BRAUN MEDICAL","regulator":"FDA","description":""},{"date":"20240220","type":"positive","milestone":"FDA approval — PAI HOLDINGS PHARM","regulator":"FDA","description":""}],"_dailymed":{"setId":"74bad838-2800-4d36-a3ee-cc1d739d24c2","title":"XYLOCAINE (LIDOCAINE HYDROCHLORIDE,EPINEPHRINE BITARTRATE) INJECTION, SOLUTION [SPORTPHARM LLC]"},"aiSummary":"Lidocaine Hydrochloride is a preservative-free topical anesthetic marketed by Pfizer for local anesthesia of oral and pharyngeal mucous membranes. It functions as a sodium channel blocker, preventing nerve impulse transmission in localized areas. The formulation is indicated for reducing discomfort during dental procedures, X-ray imaging, and management of irritated oral tissues. As a well-established local anesthetic, it offers rapid onset and predictable efficacy for short-duration procedures. The preservative-free formulation enhances safety profile for sensitive patients and frequent users.","mechanism":{"target":"Voltage-gated sodium channels (Nav)","novelty":"me-too","modality":"small molecule","drugClass":"Local anesthetic (amide class)","explanation":"","oneSentence":"","technicalDetail":"Lidocaine is a lipophilic weak base that exists in equilibrium between ionized and non-ionized forms at physiological pH. The non-ionized form penetrates nerve sheaths and cell membranes, while the ionized form blocks sodium channels from the intracellular side. It demonstrates rapid onset (2-5 minutes topically) and intermediate duration of action, with metabolism occurring primarily via hepatic N-dealkylation."},"_scrapedAt":"2026-03-27T23:28:02.646Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"launchDate":"1992","annualCostUS":"$50-200/yr","currentRevenue":"empty","peakSalesEstimate":"Generic — no single company revenue"},"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:49:11.247700+00:00","fieldsConflicting":1,"overallConfidence":0.8},"competitors":[{"name":"Bupivacaine Hydrochloride","company":"Various manufacturers","advantage":"Longer duration of action (4-8 hours vs 0.5-1 hour for lidocaine), allowing for extended anesthesia with fewer injections"},{"name":"Prilocaine Hydrochloride","company":"Various manufacturers","advantage":"Lower systemic toxicity profile and faster metabolism, making it safer for patients with liver disease"},{"name":"Mepivacaine Hydrochloride","company":"Various manufacturers","advantage":"Intermediate duration of action (1-1.5 hours) with rapid onset, offering a balance between lidocaine and bupivacaine"},{"name":"Articaine Hydrochloride","company":"Septodont, Pierrel","advantage":"Enhanced penetration and faster onset due to lipophilic properties, with lower systemic toxicity than lidocaine"},{"name":"Ropivacaine Hydrochloride","company":"AstraZeneca","advantage":"Long duration of action with reduced cardiotoxicity compared to bupivacaine, providing safer regional anesthesia"}],"indications":{"approved":[{"name":"Topical anesthesia of irritated mucous membranes of the mouth","regulator":"FDA"},{"name":"Topical anesthesia of inflamed mucous membranes of the mouth","regulator":"FDA"},{"name":"Topical anesthesia of irritated mucous membranes of the pharynx","regulator":"FDA"},{"name":"Topical anesthesia of inflamed mucous membranes of the pharynx","regulator":"FDA"},{"name":"Reducing gagging during X-ray picture taking","regulator":"FDA"},{"name":"Reducing gagging during dental impression taking","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_fixedFields":["generics(49)","patents(0)"],"patentStatus":"Off-patent — no active Orange Book patents","trialDetails":[{"nctId":"NCT07497009","phase":"NA","title":"Effect of Lidocaine Infusion Versus Dexmedemidine Infusion on the Neurocognitive Function of Elderly Patients Undergoing Endoscopic Retrograde Cholangiopancreatography(ERCP): a Randomized, Controlled Trial.","status":"COMPLETED","sponsor":"Benha University","startDate":"2024-12-23","conditions":"Neurocognitive Function of Elderly Patients Post Operation","enrollment":30},{"nctId":"NCT07191652","phase":"","title":"The Relationship Between Opioid-Free Anesthesia and Postoperative Agitation-Delirium and Quality of Recovery in Pediatric Ear, Nose, and Throat Cases Monitored With Perioperative Bispectral Index","status":"RECRUITING","sponsor":"Istanbul University - Cerrahpasa","startDate":"2026-03-25","conditions":"Ear Throat Nose Surgery, Delirium - Postoperative, Pain Postoperative","enrollment":120},{"nctId":"NCT07497737","phase":"PHASE4","title":"OMT for Adhesive Capsulitis","status":"NOT_YET_RECRUITING","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2026-04-01","conditions":"Adhesive Capsulitis of the Shoulder, Frozen Shoulder","enrollment":300},{"nctId":"NCT07494383","phase":"NA","title":"Sphenopalatine Ganglion Block for Post-Dural Puncture Headache: A Pilot Randomised Controlled Trial","status":"COMPLETED","sponsor":"ISSSTE Hospital Regional \"Gral. Ignacio Zaragoza\"","startDate":"2024-05-21","conditions":"Post-Dural Puncture Headache, Headache","enrollment":26},{"nctId":"NCT07361796","phase":"NA","title":"The Analgesic Efficacy and Safety of Venlafaxine for Prevention of Postherpetic Neuralgia in Patients With Acute Herpes Zoster","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2025-12-15","conditions":"Herpes Zoster, Pain, Postherpetic Neuralgia","enrollment":832},{"nctId":"NCT07491991","phase":"PHASE4","title":"Effects of Different Drugs for Glottic Atomization on Postoperative Sore Throat After Thyroid Surgery","status":"COMPLETED","sponsor":"Qianfoshan Hospital","startDate":"2025-03-02","conditions":"Postoperative Pain, NEBULIZATION, Thyroid Surgery","enrollment":96},{"nctId":"NCT05072314","phase":"PHASE3","title":"Long-term Outcomes of Lidocaine Infusions for Post-Operative Pain (LOLIPOP) Trial","status":"RECRUITING","sponsor":"Monash University","startDate":"2022-07-27","conditions":"Breast Cancer, Breast Cancer Female, Breast Conserving Surgery","enrollment":4300},{"nctId":"NCT07493213","phase":"NA","title":"USG-Guided Shoulder Injections in Frozen Shoulder","status":"RECRUITING","sponsor":"Konya Beyhekim Training and Research Hospital","startDate":"2026-04-01","conditions":"Frozen Shoulder, Adhesive Capsulitis, Shoulder Pain","enrollment":68},{"nctId":"NCT07094542","phase":"PHASE2","title":"Jaw Muscle Pain Post Wisdom Molar Surgery","status":"NOT_YET_RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2026-05","conditions":"Post Operative Pain, Impacted Third Molar Tooth, Muscle Pain","enrollment":80},{"nctId":"NCT07490366","phase":"NA","title":"Comparison of the Effectiveness of Exercise, Dry Needling and Interfascial Block Treatments in the Treatment of Myofascial Pain Syndrome","status":"RECRUITING","sponsor":"Eren Başıbüyük","startDate":"2025-08-01","conditions":"Myofascial Pain of Upper Trapezius Muscle","enrollment":78},{"nctId":"NCT07423650","phase":"PHASE4","title":"Continous Infusion of Nefopam for Patients Undergoing Pancreatoduodenectomy","status":"RECRUITING","sponsor":"Iuliu Hatieganu University of Medicine and Pharmacy","startDate":"2026-03","conditions":"Pancreatoduodenectomy, Pain Management, Opioid Analgesia","enrollment":93},{"nctId":"NCT07203534","phase":"NA","title":"ONC-MM-2407: The Effect of Virtual Reality Headsets on Pain and Anxiety in the Peri and Post Bone Marrow Biopsy Period","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2026-01-23","conditions":"Hematologic Malignancy","enrollment":160},{"nctId":"NCT02870738","phase":"PHASE2","title":"Bladder Directed vs. Pelvic Floor Therapy in IC/BPS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Corewell Health East","startDate":"2017-04-21","conditions":"Cystitis, Interstitial, Painful Bladder Syndrome","enrollment":128},{"nctId":"NCT07489001","phase":"","title":"Opioid Free and Opioid Based Anesthesia in Elective Lumbar Spine Surgery","status":"RECRUITING","sponsor":"Marmara University","startDate":"2025-12-09","conditions":"Lumbar Spinal Stenosis, Lumbar Disc Herniation With Radiculopathy, Lumbar Degenerative Spondylolisthesis","enrollment":75},{"nctId":"NCT07487246","phase":"PHASE2","title":"Paracervical Block With Combined Ketorolac and Lidocaine for Osmotic Dilator Placement","status":"NOT_YET_RECRUITING","sponsor":"Rush University Medical Center","startDate":"2026-05-01","conditions":"Pain Management, Abortion, Second Trimester Abortion","enrollment":76},{"nctId":"NCT07488832","phase":"NA","title":"Intravenous Lidocaine Infusion in Lumbar Fusion Surgery","status":"NOT_YET_RECRUITING","sponsor":"Ankara City Hospital Bilkent","startDate":"2026-03-20","conditions":"Lumbar Fusion Surgery","enrollment":110},{"nctId":"NCT07334002","phase":"NA","title":"The Effects of Conventional Therapy on Tinnitus, Disability, and Quality of Life in Patients With Tinnitus","status":"NOT_YET_RECRUITING","sponsor":"Sisli Hamidiye Etfal Training and Research Hospital","startDate":"2026-03-01","conditions":"Tinnitus, Neural Therapy of Huneke","enrollment":30},{"nctId":"NCT07255248","phase":"PHASE4","title":"Hoffa's Fat Pad Impingement (HFPI)","status":"RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2026-03-01","conditions":"Hoffa's Fat Pad Impingement","enrollment":62},{"nctId":"NCT07398755","phase":"","title":"Prospective, Non-interventional Study Assessing Periorbital Rejuvenation Procedure","status":"COMPLETED","sponsor":"Yuvell","startDate":"2025-09-02","conditions":"Glabellar Lines, Midface Volume Deficiency, Periorbital Wrinkling","enrollment":29},{"nctId":"NCT07224711","phase":"PHASE4","title":"The Impact of Perioperative Lidocaine Infusions on Enhanced Recovery After Non-Cardiac Surgery","status":"NOT_YET_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2026-07-01","conditions":"Pain, Post Operative Analgesia, Opioid Consumption, Postoperative","enrollment":2290},{"nctId":"NCT04992572","phase":"EARLY_PHASE1","title":"Study Comparing Local/ MAC Anesthesia in Lumbar Decompression","status":"RECRUITING","sponsor":"Stanford University","startDate":"2021-12-01","conditions":"Lumbar Spinal Stenosis","enrollment":100},{"nctId":"NCT07012382","phase":"NA","title":"Single Gene Polymorphism and the Success Rate of Inferior Alveolar Nerve Block","status":"COMPLETED","sponsor":"Jamia Millia Islamia","startDate":"2025-05-10","conditions":"Pulpitis - Irreversible","enrollment":320},{"nctId":"NCT05446623","phase":"PHASE2, PHASE3","title":"Cardiac Index and General Anesthesia Without Opioid.","status":"COMPLETED","sponsor":"Centre Hospitalier de Montauban","startDate":"2021-01-01","conditions":"Hip Arthropathy, Hip Disease","enrollment":120},{"nctId":"NCT06287372","phase":"","title":"Comparison of Changes in Intra-myocardial Amino Acids During Use of Calafiore and Modified Del Nido Cardioplegia","status":"COMPLETED","sponsor":"Damascus University","startDate":"2022-07-04","conditions":"Myocardial Injury, Cardiac Surgery, Myocardial Protection","enrollment":20},{"nctId":"NCT03844412","phase":"PHASE2","title":"Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments","status":"COMPLETED","sponsor":"Duke University","startDate":"2019-11-04","conditions":"Vestibulodynia, Temporomandibular Disorder, Fibromyalgia Syndrome","enrollment":209},{"nctId":"NCT03304496","phase":"PHASE4","title":"Subcutaneous Nitroglycerin to Facilitate Trans-radial Access.","status":"SUSPENDED","sponsor":"Instituto Nacional de Cardiologia Ignacio Chavez","startDate":"2018-03-30","conditions":"Coronary Artery Disease","enrollment":1400},{"nctId":"NCT07476235","phase":"","title":"Predictors of Treatment Response to Stellate Ganglion Block in Cervical Radicular Pain","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2024-10-08","conditions":"Radiculopathy, Cervical Region","enrollment":90},{"nctId":"NCT07480135","phase":"PHASE4","title":"Pain Experience Using Lidocaine Adrenaline Tetracaine (LAT) Gel Versus Lidocaine Infiltration for Laceration Repair in Adults","status":"COMPLETED","sponsor":"Vrije Universiteit Brussel","startDate":"2021-04-01","conditions":"Lacerations, Wound Repair, Acute Traumatic Wounds","enrollment":70},{"nctId":"NCT07471854","phase":"NA","title":"Efficacy and Safety of Combined Nanofat Injection With Either Platelet Rich Fibrin or Microneedling Versus Nanofat Injection Alone in the Treatment of Facial Atrophic Post Acne Scars","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2026-05-01","conditions":"Acne Scars - Atrophic","enrollment":42},{"nctId":"NCT05423613","phase":"NA","title":"Microneedling for Burn Hypertrophic Scars","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2021-01-22","conditions":"Burn Scar","enrollment":36},{"nctId":"NCT07473349","phase":"NA","title":"Diagnostic Accuracy of Clinical Tests and Diagnostic Criteria for Piriformis Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Istanbul University - Cerrahpasa","startDate":"2026-03-15","conditions":"Piriformis Syndrome, Gluteal Pain","enrollment":75},{"nctId":"NCT06936410","phase":"PHASE2","title":"Using Lidocaine or Dexmedetomidine to Help Control Blood Pressure Spikes From a Tourniquet During Knee Surgery","status":"COMPLETED","sponsor":"Cairo University","startDate":"2025-03-01","conditions":"Tourniquet Hypertension","enrollment":186},{"nctId":"NCT06839326","phase":"NA","title":"Efficacy of Autologous Conditioned Serum in Temporomandibular Joint Disorder","status":"COMPLETED","sponsor":"Batman University","startDate":"2024-11-01","conditions":"Temporomandibular Joint Osteoarthritis","enrollment":75},{"nctId":"NCT07248202","phase":"NA","title":"Ketamine-lidocaine Versus Ketamine-fentanyl for Induction of Anesthesia in Patients With Left Ventricular Systolic Dysfunction Undergoing Elective Coronary Artery Bypass","status":"RECRUITING","sponsor":"Cairo University","startDate":"2025-12-01","conditions":"Coronary Artery Disease (CAD), Left Ventricular (LV) Systolic Dysfunction, Induction Anesthesia","enrollment":40},{"nctId":"NCT07473414","phase":"NA","title":"Synovial Tissue as a Biomarker in the Early Management of Osteoarthritis","status":"NOT_YET_RECRUITING","sponsor":"Nantes University Hospital","startDate":"2026-04-01","conditions":"Osteoarthritis","enrollment":30},{"nctId":"NCT07475520","phase":"NA","title":"Lidocaine IV Injection With Different Doses for Patients With Neuropathic Pain After Mastectomy","status":"COMPLETED","sponsor":"Cairo University","startDate":"2022-07-25","conditions":"Neuropathic Pain Induced by Mastectomy","enrollment":30},{"nctId":"NCT07264829","phase":"NA","title":"This Clinical Trial Aims to Compare the Effectiveness of Two Intra-pulpal Cryotherapy Techniques-Endo-ice and Ice Sticks-in Decreasing Intra-operative Pain and Enhancing the Success of Local Anesthesia During Pulpectomy of Mandibular Molars With Symptomatic Irreversible Pulpitis.","status":"NOT_YET_RECRUITING","sponsor":"Dow University of Health Sciences","startDate":"2026-04-15","conditions":"Root Canal Treatment, Intra-operative Pain, Symptomatic Irreversible Pulpitis","enrollment":90},{"nctId":"NCT07398768","phase":"","title":"Prospective, Non-interventional Study Assessing Perioral Rejuvenation Procedure","status":"RECRUITING","sponsor":"Yuvell","startDate":"2026-02-13","conditions":"Perioral Wrinkles, Crow's Feet, Lip Volume Enhancement","enrollment":34},{"nctId":"NCT07047638","phase":"NA","title":"A Study to Evaluate the Effectiveness and Safety of Restylane Skinboosters Vital Lidocaine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Galderma R&D","startDate":"2025-07-09","conditions":"Skin Quality Improvement","enrollment":171},{"nctId":"NCT04931745","phase":"NA","title":"Virtual Reality for Port-a-Cath Access","status":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2022-04-26","conditions":"Oncology Pain","enrollment":84},{"nctId":"NCT07443553","phase":"NA","title":"Alcohol Neurolysis and Capsaicin for Postamputation Pain (PAP)","status":"NOT_YET_RECRUITING","sponsor":"Northwestern University","startDate":"2026-02-15","conditions":"Postamputation Pain","enrollment":120},{"nctId":"NCT05944861","phase":"NA","title":"Combination of Fluoroscopy and Ultrasonography Guidance in Sacroiliac Joint Injections. A Randomised Controlled Trial","status":"COMPLETED","sponsor":"Gaziler Physical Medicine and Rehabilitation Education and Research Hospital","startDate":"2023-02-15","conditions":"Sacroiliac Joint Somatic Dysfunction, Sacroiliac Joint Pain","enrollment":38},{"nctId":"NCT07462988","phase":"NA","title":"Comparison of Mesotherapy Treatment Doses in Patients With Chronic Non-Specific Neck Pain","status":"COMPLETED","sponsor":"Istanbul Medeniyet University","startDate":"2025-01-01","conditions":"Neck Pain, Mesotherapy","enrollment":80},{"nctId":"NCT07000760","phase":"PHASE3","title":"Intraoperative Nebulization of Lidocaine and Postoperative Pulmonary Complications","status":"COMPLETED","sponsor":"Jun Zhang","startDate":"2025-06-06","conditions":"Postoperative Pulmonary Complications (PPCs)","enrollment":270},{"nctId":"NCT06223659","phase":"PHASE2","title":"EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers","status":"RECRUITING","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2023-12-19","conditions":"Cutaneous Melanoma, Merkel Cell Carcinoma, Skin Squamous Cell Carcinoma","enrollment":100},{"nctId":"NCT06782529","phase":"PHASE4","title":"Knee Injections for Obese Patients With Knee Arthritis","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-01-24","conditions":"Osteoarthritis of Knee","enrollment":40},{"nctId":"NCT04716699","phase":"PHASE1","title":"Systemic and Local Levels of Lidocaine During Surgery for the Removal of Glioblastoma","status":"COMPLETED","sponsor":"University of California, Davis","startDate":"2021-01-20","conditions":"Glioblastoma","enrollment":12},{"nctId":"NCT04805242","phase":"NA","title":"Effects of Dextrose Prolotherapy in Rotator Cuff Disease","status":"COMPLETED","sponsor":"Istanbul University","startDate":"2021-03-18","conditions":"Rotator Cuff Disease","enrollment":60},{"nctId":"NCT04828083","phase":"PHASE4","title":"Systemic Lidocaine Versus Ultrasound-guided Adductor Canal Block for Patients Undergoing Total Knee Arthroplasty","status":"COMPLETED","sponsor":"Rhode Island Hospital","startDate":"2021-03-01","conditions":"Arthroplasty, Replacement, Knee, Total Knee Arthroplasty","enrollment":120},{"nctId":"NCT06999408","phase":"NA","title":"Efficacy and Safety of TargetCool + Benev Exosomes in Patients With Hair Thinning","status":"ACTIVE_NOT_RECRUITING","sponsor":"Recens Medical, Inc.","startDate":"2025-09-16","conditions":"Hair Diseases, Alopecia, Hair Thinning","enrollment":15},{"nctId":"NCT05907811","phase":"NA","title":"General Anesthesia and General Anesthesia Combined With Thoracic Epidural Anesthesia","status":"COMPLETED","sponsor":"Yuzuncu Yil University","startDate":"2023-06-05","conditions":"Thoracal Epidural Block","enrollment":60},{"nctId":"NCT05044468","phase":"PHASE2","title":"EXPAREL or Lidocane as Local Anesthetic in Patients Undergoing Pleuroscopy With Pleural Biopsy and Indwelling Pleural Catheter Placement","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-03-23","conditions":"Malignant Pleural Neoplasm","enrollment":80},{"nctId":"NCT07456826","phase":"PHASE4","title":"Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal Injections","status":"NOT_YET_RECRUITING","sponsor":"Harrow Inc","startDate":"2026-04","conditions":"Diabetic Macular Edema (DME), Age-Related Macular Degeneration (AMD), Retinal Vein Occlusion","enrollment":236},{"nctId":"NCT07333859","phase":"PHASE4","title":"Effect of IV Lidocaine on Duodenal Peristalsis and Sedation in ERCP","status":"RECRUITING","sponsor":"Ankara City Hospital Bilkent","startDate":"2026-02-11","conditions":"Duodenal Spasm, ERCP, Sedation","enrollment":120},{"nctId":"NCT07456735","phase":"PHASE4","title":"Comparison of the Effectiveness of Dry Needling Versus the Combination of Dry Needling and Local Anesthetic Injection in Myofascial Pain Syndrome of the Upper Trapezius Muscle: A Sham-Controlled, Randomized Clinical Trial","status":"NOT_YET_RECRUITING","sponsor":"Emre Ata, Assoc Prof","startDate":"2026-03-01","conditions":"Myofascial Pain of Upper Trapezius Muscle","enrollment":90},{"nctId":"NCT07432399","phase":"PHASE2","title":"Effect of Perioperative Lidocaine or High-Dose Dexamethasone on Immune Response in Colon Cancer Surgery (PILDI Study)","status":"RECRUITING","sponsor":"Institute of Oncology Ljubljana","startDate":"2025-09-01","conditions":"Colon Cancer, Colorectal Cancer, Perioperative Immune Response","enrollment":100},{"nctId":"NCT05589402","phase":"PHASE1","title":"Temporary Inactivation of Strong Muscle Sensation to Improve Rehabilitation Interventions in SCI","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Texas Rio Grande Valley","startDate":"2019-06-04","conditions":"Spinal Cord Injuries, Spine Disease, Stroke","enrollment":30},{"nctId":"NCT05844930","phase":"PHASE4","title":"A Study to Determine the Safety and Effectiveness of a Connective Tissue Allograft (ActiveMatrix) Verses Standard of Care in Adhesive Capsulitis of the Shoulder","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2023-01-03","conditions":"Adhesive Capsulitis","enrollment":56},{"nctId":"NCT07401745","phase":"PHASE4","title":"Occlusal Splint Combined With Granisetron Injection for Management of Myofascial Pain Related to Temporomandibular Disorders","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mansoura University","startDate":"2026-01-27","conditions":"TMD, TMD/Orofacial Pain, Temporomandibular Disorder (TMD)","enrollment":48},{"nctId":"NCT06772727","phase":"PHASE4","title":"Lidocaine-based Versus Opioid-based Induction of Anesthesia in Emergency Laparotomy","status":"COMPLETED","sponsor":"Cairo University","startDate":"2025-02-01","conditions":"Post-induction Hypotension, Lidocaine, Opioid","enrollment":149},{"nctId":"NCT07268118","phase":"PHASE2","title":"Pain Control for Cervical Ripening Balloon","status":"NOT_YET_RECRUITING","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2026-04","conditions":"Labor Induction","enrollment":110},{"nctId":"NCT07448246","phase":"NA","title":"Effect of Bilateral Rhomboid Intercostal Block on Postoperative Pain After Breast Implant Surgery","status":"RECRUITING","sponsor":"Aydin Adnan Menderes University","startDate":"2026-02-15","conditions":"Breast Prosthesis; Pain, Postoperative Pain, Breast Augmentation","enrollment":40},{"nctId":"NCT07035301","phase":"NA","title":"Application of Low-dose Muscle Relaxants in Bronchoscopic Interventional Procedures","status":"COMPLETED","sponsor":"Harbin Medical University","startDate":"2025-03-17","conditions":"Disease of Respiratory System","enrollment":153},{"nctId":"NCT07447479","phase":"PHASE4","title":"Functional Outcomes After LumbOpenitoneal Shunt Placement UndeR Local Anesthesia for Patients With Idiopathic Normal preSsure Hydrocephalus (FLOURISH) Trial","status":"NOT_YET_RECRUITING","sponsor":"Institute for Clinical Effectiveness, Japan","startDate":"2026-04-01","conditions":"Idiopathic Normal Pressure Hydrocephalus (INPH)","enrollment":196},{"nctId":"NCT07445191","phase":"PHASE2, PHASE3","title":"Efficacy of Triamcinolone-Lidocaine Mix in Trigger Points Injection of Masseter Muscle: Double-blinded, Randomized Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"Cairo University","startDate":"2026-03-01","conditions":"TMJ Pain","enrollment":30},{"nctId":"NCT06962085","phase":"NA","title":"Sacral Erector Spinae Plane Block in Transurethral Prostate Resection Surgery","status":"COMPLETED","sponsor":"Adiyaman University","startDate":"2025-09-05","conditions":"TURP(Transurethral Resection of Prostate)","enrollment":60},{"nctId":"NCT07445386","phase":"NA","title":"Transdiscal vs Paravertebral Neurolytic Splanchnic Nerve Block for Upper Abdominal Cancer Pain","status":"RECRUITING","sponsor":"Ankara Etlik City Hospital","startDate":"2026-02-16","conditions":"Cancer Pain","enrollment":56},{"nctId":"NCT04479735","phase":"NA","title":"Virtual Reality Goggle Utilization for Venipuncture Distraction","status":"COMPLETED","sponsor":"Montefiore Medical Center","startDate":"2021-07-16","conditions":"Pain, Procedural","enrollment":126},{"nctId":"NCT02234193","phase":"EARLY_PHASE1","title":"Reducing Side-effects of Autologous Skin Tissue Harvesting","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2016-06-01","conditions":"Scar","enrollment":8},{"nctId":"NCT05279937","phase":"PHASE3","title":"The Ultrasound-Guided Dextrose Prolotherapy in Ehlers-Danlos Syndrome Patients","status":"NOT_YET_RECRUITING","sponsor":"Tulane University","startDate":"2026-06","conditions":"Ehlers-Danlos Syndrome, Low Back Pain, Sacroiliac Instability","enrollment":40},{"nctId":"NCT07434739","phase":"NA","title":"PAravertebral CaTheter Versus Epidural Analgesia in Totally Minimally Invasive Esophagectomies","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Lille","startDate":"2026-05-01","conditions":"Esophageal Cancer, Esophagectomy, Multimodal Analgesia","enrollment":506},{"nctId":"NCT07436546","phase":"NA","title":"Prospective Evaluation of Efficacy of Tumescent Steroid Infiltration in Mandibular Third Molar Surgery: a Split Mouth Randomized Study","status":"COMPLETED","sponsor":"Postgraduate Institute of Dental Sciences Rohtak","startDate":"2025-03-23","conditions":"Impacted Third Molar, Impacted Third Molar Tooth, Third Molar Extraction","enrollment":25},{"nctId":"NCT06299735","phase":"NA","title":"Comparison of Airway Management With Bronchial Blocker and Double-Lumen Tube in Single-Lung Ventilation","status":"COMPLETED","sponsor":"Ankara City Hospital Bilkent","startDate":"2024-04-17","conditions":"Heart Valvular Disease, Coronary Arteriosclerosis, One-lung Ventilation","enrollment":66},{"nctId":"NCT06122324","phase":"NA","title":"Effect of Lidocaine on Hemodynamic Response and Postoperative Sore Throat","status":"COMPLETED","sponsor":"Dr. Lutfi Kirdar Kartal Training and Research Hospital","startDate":"2023-12-01","conditions":"Postoperative Sore Throat","enrollment":100},{"nctId":"NCT07440199","phase":"NA","title":"Comparison of SPSIP Block and SAP Block in Non-Intubated Uniportal VATS.","status":"RECRUITING","sponsor":"Firat University","startDate":"2026-01-16","conditions":"This Study Evaluates the Effects of Different Fascial Plane Blocks on Intraoperative Anesthesia and Analgesic Consumption in Non-intubated VATS Procedures","enrollment":70},{"nctId":"NCT07354464","phase":"PHASE3","title":"Efficacy of Sphenopalatine Block Compared to Blood Patch in the Management of Post-dural Puncture Headaches","status":"RECRUITING","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2026-02-19","conditions":"PDPH, Post Dural Puncture Headache","enrollment":80},{"nctId":"NCT04990128","phase":"PHASE3","title":"Bone Marrow Aspirate Concentrate Versus Triamcinolone Injection For Hip Osteoarthritis","status":"NOT_YET_RECRUITING","sponsor":"The Cleveland Clinic","startDate":"2026-03-01","conditions":"Hip Osteoarthritis","enrollment":100},{"nctId":"NCT07430085","phase":"PHASE4","title":"Post-Operative Pain Relief: Zynrelef or Periarticular Injections in RATKA","status":"NOT_YET_RECRUITING","sponsor":"Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)","startDate":"2026-01-31","conditions":"Periarticular Block, Osteoarthritis (OA), Osteoarthritis (OA) of the Knee","enrollment":150},{"nctId":"NCT06543368","phase":"NA","title":"Low-Cost Platelet-Rich Plasma for Hemarthropathy","status":"COMPLETED","sponsor":"University of Utah","startDate":"2024-07-23","conditions":"Hemarthrosis, Hemophilia","enrollment":14},{"nctId":"NCT07120230","phase":"NA","title":"Tubeless Strategy in Lung Transplantation: A Prospective Single-Arm Study","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Guangzhou Medical University","startDate":"2025-08-03","conditions":"Lung Transplant Recipient","enrollment":30},{"nctId":"NCT07337135","phase":"NA","title":"Opioid-Free vs Opioid-Based Anesthesia in Bariatric Surgery","status":"COMPLETED","sponsor":"Hospital dos Lusíadas","startDate":"2023-10-02","conditions":"Morbid Obesity, Postoperative Pain, Opioid Free Anesthesia","enrollment":60},{"nctId":"NCT06236126","phase":"NA","title":"SKIN WHEAL - Subcutaneous or Intradermal Lidocaine in Epidural for Laboring Pain.","status":"COMPLETED","sponsor":"Ohio State University","startDate":"2023-11-13","conditions":"Analgesia, Obstetrical","enrollment":51},{"nctId":"NCT07431905","phase":"NA","title":"Effect of Erector Spinae Plane Block on Postoperative Analgesia and Stress Response in Laparoscopic Sleeve Gastrectomy","status":"COMPLETED","sponsor":"Harran University","startDate":"2023-02-05","conditions":"Bariatric Sleeve Gastrectomy, Erector Spina Plan Block, Cortisol","enrollment":60},{"nctId":"NCT06726434","phase":"NA","title":"Evaluation of Percutaneous Cryoneurotomy Compared to Surgical Open Neurotomy for the Management of Equinovarus Foot Deformity in Patients With Refractory Lower Limb Spasticity After Stroke","status":"RECRUITING","sponsor":"Poitiers University Hospital","startDate":"2025-07-09","conditions":"Stroke, Equinovarus Foot, Refractory Lower Limb Spasticity","enrollment":114},{"nctId":"NCT07433257","phase":"","title":"The Effect of Local Corticosteroid Injection in Carpal Tunnel Syndrome Patients With Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Haydarpasa Numune Training and Research Hospital","startDate":"2026-03-01","conditions":"Carpal Tunnel Syndrome (CTS), Type 2 Diabetes Mellitus (T2DM)","enrollment":60},{"nctId":"NCT07433231","phase":"NA","title":"Magnesium Sulfate Versus Other Anesthesia Drugs to Reduce Agitation After Adenotonsillectomy in Pediatric Patients","status":"COMPLETED","sponsor":"Ayfer Kaya Gök","startDate":"2023-11-01","conditions":"Anesthesia Emergence Delirium, Adenotonsillar Hypertrophy","enrollment":100},{"nctId":"NCT07421622","phase":"NA","title":"Management of Epistaxis Comparing Nasal Packing Versus Greater Palatine Foramen Block","status":"NOT_YET_RECRUITING","sponsor":"Sheikh Zayed Federal Postgraduate Medical Institute","startDate":"2026-03-01","conditions":"Epistaxis Nosebleed, Greater Palatine Foramen","enrollment":40},{"nctId":"NCT07429708","phase":"PHASE3","title":"Dexamethasone as ESPB Adjuvant in Lumbar Laminectomy","status":"COMPLETED","sponsor":"Udayana University","startDate":"2025-03-10","conditions":"Laminectomy, Postperative Pain Management, Prostaglandin E2","enrollment":36},{"nctId":"NCT06811701","phase":"","title":"Evaluation of Response to Pain From Skull Pin Fixation in Craniotomies","status":"COMPLETED","sponsor":"Diskapi Teaching and Research Hospital","startDate":"2025-02-28","conditions":"Electroencephalography, Craniotomy Surgery, Pain Management","enrollment":120},{"nctId":"NCT07429292","phase":"NA","title":"SPARK Study - Sympathetic Periarterial Radial Block in Healthy Volunteers","status":"NOT_YET_RECRUITING","sponsor":"Duke University","startDate":"2026-05","conditions":"Healthy Volunteers, Sympathetic Activity","enrollment":20},{"nctId":"NCT07427082","phase":"NA","title":"Comparison of Lumbar Erector Spinae Plane Block and Spinal Anesthesia in Hip and Proximal Femur Surgery","status":"COMPLETED","sponsor":"Muhammed Gökhan Abay","startDate":"2022-07-01","conditions":"Hip Surgery, Femoral Neck Fractures","enrollment":66},{"nctId":"NCT06349057","phase":"PHASE4","title":"The Effect of the Anticholinergic Burden Following Elective Coronary Artery Surgery","status":"COMPLETED","sponsor":"Ankara City Hospital Bilkent","startDate":"2024-01-01","conditions":"Postoperative Recovery, Length of Hospital Stay, Postoperative Complications","enrollment":120},{"nctId":"NCT05978687","phase":"PHASE4","title":"The Use of Lidocaine Gel Versus Subconjunctival Xylocaine Injection in Pterygium Excision","status":"COMPLETED","sponsor":"Vrije Universiteit Brussel","startDate":"2023-09-01","conditions":"Pterygium","enrollment":41},{"nctId":"NCT07426523","phase":"NA","title":"Effectiveness of Needle-Free Infiltration Anesthesia in Reduction of Dental Pain and Anxiety During Local Anesthesia.","status":"COMPLETED","sponsor":"Damascus University","startDate":"2025-05-28","conditions":"This Study Aims to Evaluate the Effectiveness of the INJEX Device in Administering Local Anesthesia","enrollment":52},{"nctId":"NCT07427238","phase":"","title":"Pericapsular Nerve Group Block Added to Intra-articular Corticosteroid Injection in the Treatment of Hip Pain","status":"COMPLETED","sponsor":"Saglik Bilimleri Universitesi","startDate":"2025-02-01","conditions":"Hip Pain Chronic, Osteoarthritis, Hip","enrollment":50},{"nctId":"NCT07425678","phase":"PHASE4","title":"Comparison of Systemic Opioid (Morphine) and Pre-Incision Bilateral Scalp Nerve Block for Pain Management in Craniotomy Patients","status":"COMPLETED","sponsor":"Aga Khan University","startDate":"2025-01-01","conditions":"Supratentorial Tumors","enrollment":62},{"nctId":"NCT04472702","phase":"NA","title":"Fluoroscopic Versus Ultrasound Guidance for Cooled Radiofrequency Ablation of Geniculate Nerves in Knee Osteoarthritis: A Randomized Control Trial","status":"RECRUITING","sponsor":"University of California, Davis","startDate":"2022-02-02","conditions":"Knee Osteoarthritis","enrollment":90},{"nctId":"NCT07422558","phase":"NA","title":"Intravenous Nalbuphine Versus Lidocaine for Prevention of Propofol Injection Pain","status":"NOT_YET_RECRUITING","sponsor":"Hayatabad Medical Complex","startDate":"2026-03-01","conditions":"Procedural Pain","enrollment":92},{"nctId":"NCT07211399","phase":"EARLY_PHASE1","title":"Transition From Acute to Chronic Opioid Use and Chronic Pain","status":"NOT_YET_RECRUITING","sponsor":"Jacques E. Chelly","startDate":"2026-03-01","conditions":"Opioid Use Disorder","enrollment":700},{"nctId":"NCT07408193","phase":"EARLY_PHASE1","title":"The Role of Coadministration of Lidocaine and Ketamine in Opioid-Refractory Chronic Cancer-Related Pain.","status":"NOT_YET_RECRUITING","sponsor":"National and Kapodistrian University of Athens","startDate":"2026-03","conditions":"Opioid-Refractory Chronic Cancer-Related Pain","enrollment":24}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"FEELING HOT"},{"count":2,"reaction":"OEDEMA PERIPHERAL"},{"count":1,"reaction":"ASTHENIA"},{"count":1,"reaction":"CHEST DISCOMFORT"},{"count":1,"reaction":"INJECTION SITE ERYTHEMA"},{"count":1,"reaction":"INJECTION SITE SWELLING"},{"count":1,"reaction":"MALAISE"},{"count":1,"reaction":"NERVOUSNESS"}],"administration":{"route":"Oral"},"_patentsChecked":true,"crossReferences":{"chemblId":"CHEMBL1200409"},"_approvalHistory":[],"publicationCount":1000,"genericManufacturers":49,"_genericFilersChecked":true,"genericManufacturerList":["Abbott","Abraxis Pharm","Actavis Mid Atlantic","Afaxys","Am Regent","Anthea Pharma","Aspiro","Aurobindo Pharma Ltd","B Braun Medical","Bel Mar","Belmora Llc","Bionpharma","Carlisle","Chartwell Molecular","Cosette","Dell Labs","Elkins Sinn","Epic Pharma Llc","Eugia Pharma","Extrovis","Fresenius Kabi Usa","Gd Searle Llc","Hikma","Hospira","Huons","Intl Medication","Kendall Il","Lannett Co Inc","Luitpold","Lyphomed","Mankind Pharma","Miles","Novitium Pharma","Paco","Pai Holdings Pharm","Pharmaton","Pharmobedient","Rising","Rubicon Research","Sagent Pharms Inc","Sentiss","Spectra Mdcl Devices","Sun Pharma Canada","The J Molner","Watson Labs","Watson Labs Inc","West-Ward Pharms Int","Wyeth Ayerst","Yiling"],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"approved","brandName":"Lidocaine Hydrochloride Preservative Free","genericName":"Lidocaine Hydrochloride","companyName":"Pfizer Inc.","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"1992","enrichmentLevel":4,"visitCount":10,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2003-02-12T00:00:00.000Z","mah":"SENTISS","brand_name_local":null,"application_number":"ANDA040433"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2018-04-18T00:00:00.000Z","mah":"SPECTRA MDCL DEVICES","brand_name_local":null,"application_number":"ANDA208017"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2019-10-29T00:00:00.000Z","mah":"SAGENT PHARMS INC","brand_name_local":null,"application_number":"ANDA201094"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2021-06-08T00:00:00.000Z","mah":"DEPROCO","brand_name_local":null,"application_number":"ANDA088389"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2022-03-23T00:00:00.000Z","mah":"NOVITIUM PHARMA","brand_name_local":null,"application_number":"ANDA216250"},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":20,"withResults":5},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:49:11.247700+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}